Vendor Matrix
Medical Device AI Vendor Guide
Side-by-side comparison of medical device AI platforms across quality control/vision AI, regulatory (FDA) AI, predictive maintenance AI, and design AI by device class.
This matrix compares AI platform categories for medical device companies across both dimensions of the device AI challenge: embedding intelligence into products (AI as the device) and using AI to improve design, manufacturing, and compliance (AI for the device company). Both paths run through the FDA. Over 900 AI-enabled medical devices have received clearance, with submissions accelerating — more cleared in 2023-2024 than in all prior years combined. The PCCP framework now allows devices to learn post-market without new clearances. Use this matrix alongside the AI for Medical Devices decision guide.
Platform Comparison by Capability
| Evaluation Criteria | Quality Control / Vision AI | Regulatory (FDA) AI | Predictive Maintenance AI | Design AI (SaMD) |
|---|---|---|---|---|
| Core Function | Visual inspection, defect detection | Submission prep, post-market surveillance | Equipment monitoring, failure prediction | Diagnostic algorithms, monitoring |
| Primary Value | Quality consistency, recall prevention | Submission speed, compliance | Uptime, out-of-spec prevention | Product differentiation |
| FDA Regulatory Impact | Indirect (QSR 820 compliance) | Supportive (submission preparation) | Indirect (process validation) | Direct (SaMD clearance required) |
| Clinical Data Required | Manufacturing data only | Post-market surveillance data | Equipment sensor data | Extensive clinical validation |
| QMS Integration | Critical (ISO 13485, 21 CFR 820) | Important (document control) | Moderate (maintenance records) | Critical (design controls) |
| Risk Profile | Moderate (product quality) | Low | Low-Moderate | High (patient safety) |
| Development Timeline | 3-9 months | 2-4 months | 3-6 months | 12-24 months (incl. clearance) |
| Typical Pricing Model | Per-line / per-camera license | Platform license / per-submission | Per-machine / platform license | Royalty / per-unit / license |
Selection Criteria by Device Class
| Factor | Class I (Low Risk) | Class II (Moderate Risk) | Class III (High Risk) |
|---|---|---|---|
| Primary AI Priority | Manufacturing quality + efficiency | Quality + embedded intelligence | Clinical AI + rigorous validation |
| FDA AI Pathway | Generally exempt from 510(k) | 510(k) or De Novo with PCCP | PMA with extensive clinical evidence |
| Validation Requirements | Standard process validation | Clinical and analytical validation | Full clinical trials, multi-site |
| Post-Market AI Updates | Standard change control | PCCP framework eligible | PMA supplement or PCCP (limited) |
| Budget Range (AI Annual) | $100K-$500K | $500K-$5M | $5M-$30M+ |
Vendor Shortlist Criteria
- FDA regulatory pathway experience — vendor track record with 510(k), De Novo, or PMA submissions for AI-enabled devices
- ISO 13485 compatibility — AI development tools and processes that integrate directly with your quality management system
- Design control alignment — AI development lifecycle mapped to 21 CFR 820.30 design control requirements from concept to release
- Bias and performance testing — validated across diverse patient populations with documented performance boundaries and edge cases
- Cybersecurity framework — alignment with FDA premarket cybersecurity guidance for connected and networked medical devices
- PCCP readiness — demonstrated ability to support predetermined change control plans for post-market algorithm evolution
Key decision point
The companies that treat FDA compliance as a design parameter from day one — not an obstacle to navigate at the end — consistently achieve faster clearances and more robust products. The PCCP framework rewards this approach: for the first time, you can design an AI device that gets smarter after clearance with FDA's advance agreement. Engage the FDA early through Pre-Submission meetings. Treat them as a design partner, not a gatekeeper.